148
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Reversible Affective Symptoms and Attention Executive Control Network Impairment Following Thyroid Function Normalization in Hyperthyroidism

ORCID Icon, ORCID Icon, ORCID Icon, , , & show all
Pages 3305-3312 | Published online: 26 Nov 2019

References

  • Kravets I. Hyperthyroidism: diagnosis and treatment. Am Fam Physician. 2016;93(5):363–370.26926973
  • Azizi F, Yousefi V, Bahrainian A, Sheikholeslami F, Tohidi M, Mehrabi Y. Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch Iran Med. 2012;15(8):477–484. doi:10.12158/AIM.00722827783
  • Lee JE, Lee DH, Oh TJ, et al. Validity and reliability of the Korean version of the hyperthyroidism symptom scale. Endocrinol Metab. 2018;33(1):70–78. doi:10.3803/EnM.2018.33.1.70
  • Yuan L, Tian Y, Zhang F, et al. Decision-making in patients with hyperthyroidism: a neuropsychological study. PLoS One. 2015;10(6):e0129773. doi:10.1371/journal.pone.012977326090955
  • Riguetto CM, Neto AM, Tambascia MA, Zantut-Wittmann DE. The relationship between quality of life, cognition, and thyroid status in Graves’ disease. Endocrine. 2019;63(1):87–93. doi:10.1007/s12020-018-1733-y30173328
  • Vogel A, Elberling TV, Hording M, et al. Affective symptoms and cognitive functions in the acute phase of Graves’ thyrotoxicosis. Psychoneuroendocrinology. 2007;32(1):36–43. doi:10.1016/j.psyneuen.2006.09.01217097812
  • Alvarez MA, Gomez A, Alavez E, Navarro D. Attention disturbance in Graves’ disease. Psychoneuroendocrinology. 1983;8(4):451–454. doi:10.1016/0306-4530(83)90026-46689536
  • Fahrenfort JJ, Wilterdink AM, van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology. 2000;25(2):201–211. doi:10.1016/S0306-4530(99)00050-510674283
  • Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C, Tokatlioglu B. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res. 2006;37(1):133–139. doi:10.1016/j.arcmed.2005.05.00816314199
  • Larisch R, Kley K, Nikolaus S, et al. Depression and anxiety in different thyroid function states. Horm Metab Res. 2004;36(9):650–653. doi:10.1055/s-2004-82592515486818
  • Calissendorff J, Mikulski E, Larsen EH, Moller M. A prospective investigation of Graves’ disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms. Eur Thyroid J. 2015;4(2):93–98. doi:10.1159/00038176826279994
  • Yuan L, Tian Y, Zhang F, et al. Impairment of attention networks in patients with untreated hyperthyroidism. Neurosci Lett. 2014;574:26–30. doi:10.1016/j.neulet.2014.05.01624852828
  • Fukui T, Hasegawa Y, Takenaka H. Hyperthyroid dementia: clinicoradiological findings and response to treatment. J Neurol Sci. 2001;184(1):81–88. doi:10.1016/S0022-510X(00)00487-111231037
  • Fan J, McCandliss BD, Sommer T, Raz A, Posner MI. Testing the efficiency and independence of attentional networks. J Cogn Neurosci. 2002;14(3):340–347. doi:10.1162/08989290231736188611970796
  • Ittermann T, Volzke H, Baumeister SE, Appel K, Grabe HJ. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1417–1425. doi:10.1007/s00127-015-1043-025777685
  • Li L, Zhi M, Hou Z, Zhang Y, Yue Y, Yuan Y. Abnormal brain functional connectivity leads to impaired mood and cognition in hyperthyroidism: a resting-state functional MRI study. Oncotarget. 2017;8(4):6283–6294. doi:10.18632/oncotarget.1406028009983
  • Fischer S, Ehlert U. Hypothalamic-pituitary-thyroid (HPT) axis functioning in anxiety disorders. A systematic review. Depress Anxiety. 2018;35(1):98–110. doi:10.1002/da.2018.35.issue-129064607
  • Schreckenberger MF, Egle UT, Drecker S, et al. Positron emission tomography reveals correlations between brain metabolism and mood changes in hyperthyroidism. J Clin Endocrinol Metab. 2006;91(12):4786–4791. doi:10.1210/jc.2006-057316968792
  • Elberling TV, Danielsen ER, Rasmussen AK, Feldt-Rasmussen U, Waldemar G, Thomsen C. Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotoxic Graves’ disease. Neurology. 2003;60(1):142–145. doi:10.1212/01.WNL.0000038911.07643.BF12525741
  • Bhatara VS, Tripathi RP, Sankar R, Gupta A, Khushu S. Frontal lobe proton magnetic-resonance spectroscopy in Graves’ disease: a pilot study. Psychoneuroendocrinology. 1998;23(6):605–612. doi:10.1016/S0306-4530(98)00028-69802130
  • Petersen SE, Posner MI. The attention system of the human brain: 20 years after. Annu Rev Neurosci. 2012;35:73–89. doi:10.1146/annurev-neuro-062111-15052522524787
  • Claustre J, Balende C, Pujol JF. Influence of the thyroid hormone status on tyrosine hydroxylase in central and peripheral catecholaminergic structures. Neurochem Int. 1996;28(3):277–281. doi:10.1016/0197-0186(95)00088-78813245
  • Bernal J, Guadano-Ferraz A, Morte B. Perspectives in the study of thyroid hormone action on brain development and function. Thyroid. 2003;13(11):1005–1012. doi:10.1089/10507250377086717414651784
  • Accorroni A, Chiellini G, Origlia N. Effects of thyroid hormones and their metabolites on learning and memory in normal and pathological conditions. Curr Drug Metab. 2017;18(3):225–236. doi:10.2174/138920021866617011611240728093992
  • Mano T, Sakamoto H, Fujita K, et al. Effects of thyroid hormone on catecholamine and its metabolite concentrations in rat cardiac muscle and cerebral cortex. Thyroid. 1998;8(4):353–358. doi:10.1089/thy.1998.8.3539588501
  • Miao Q, Zhang S, Guan YH, et al. Reversible changes in brain glucose metabolism following thyroid function normalization in hyperthyroidism. AJNR Am J Neuroradiol. 2011;32(6):1034–1042. doi:10.3174/ajnr.A244921596814